Utilizing epigenetic regulators to improve HSC-based lentiviral gene therapy
Parisa Tajer (Leiden University Medical Center)
Emin Onur Karakaslar (Leiden University Medical Center, TU Delft - Pattern Recognition and Bioinformatics)
Kirsten Canté-Barrett (Leiden University Medical Center)
Brigitta A.E. Naber (Leiden University Medical Center)
Sandra A. Vloemans (Leiden University Medical Center)
Marja van Eggermond (Leiden University Medical Center)
Marie-Louise P. van der Hoorn (Leiden University Medical Center)
Erik B. van den Akker (Leiden University Medical Center, TU Delft - Pattern Recognition and Bioinformatics)
Karin Pike-Overzet (Leiden University Medical Center)
Frank J.T. Staal (Leiden University Medical Center)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
The curative benefits of autologous and allogeneic transplantation of hematopoietic stem cells (HSCs) have been proven in various diseases. However, the low number of true HSCs that can be collected from patients and the subsequent in vitro maintenance and expansion of true HSCs for genetic correction remains challenging. Addressing this issue, we here focused on optimizing culture conditions to improve ex vivo expansion of true HSCs for gene therapy purposes. In particular, we explored the use of epigenetic regulators to enhance the effectiveness of HSC-based lentiviral (LV) gene therapy. The histone deacetylase inhibitor quisinostat and bromodomain inhibitor CPI203 each promoted ex vivo expansion of functional HSCs, as validated by xenotransplantation assays and single-cell RNA sequencing analysis. We confirmed the stealth effect of LV transduction on the loss of HSC numbers in commonly used culture protocols, whereas the addition of quisinostat or CPI203 improved the expansion of HSCs in transduction protocols. Notably, we demonstrated that the addition of quisinostat improved the LV transduction efficiency of HSCs and early progenitors. Our suggested culture conditions highlight the potential therapeutic effects of epigenetic regulators in HSC biology and their clinical applications to advance HSC-based gene correction.
help_outline